Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers

• Published in: Drugs in R&D Vol. 18; no. 2; pp. 149 - 159
• Main Authors: Cullberg, Marie, Arfvidsson, Cecilia, Larsson, Bengt, Malmgren, Anna, Mitchell, Patrick, Wählby Hamrén, Ulrika, Wray, Heather
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.06.2018; Springer Nature B.V
• Subjects: Adolescent; Adult; Age; Age Factors; Aged; Asthma; Bioavailability; Biological Availability; Capsules - pharmacokinetics; Carbohydrates; Chronic obstructive pulmonary disease; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug dosages; Drug Interactions; Ethnicity; Female; Food; Food-Drug Interactions; Healthy Volunteers; Humans; Internal Medicine; Investigations; Ketoconazole - pharmacology; Male; Males; Medicine; Medicine & Public Health; Metabolism; Middle Aged; Molecules; NCT; NCT00953888; NCT01051505; NCT01083238; NCT01100047; NCT01332903; NCT01480739; NCT01735240; NCT01989520; Neutrophils; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Pyrimidines - blood; Pyrimidines - pharmacokinetics; Pyrimidines - urine; Solutions - pharmacokinetics; Sulfonamides - blood; Sulfonamides - pharmacokinetics; Sulfonamides - urine; Suspensions - pharmacokinetics; Tablets - pharmacokinetics; White people; Young Adult

Objective The aim of this study was to summarise the pharmacokinetic findings from eight phase I studies in healthy volunteers given oral AZD5069, a selective small-molecule CXCR2 antagonist. Methods 240 healthy volunteers across eight phase I studies received single (0.1–200 mg) or multiple once- o...